Cannabis Campaigners' Guide News Database result:


After you have finished reading this article you can click here to go back.

Cannabis Conference: Shaping A New Agenda

Alun Buffry

Review

Tuesday 26 Feb 2002

---

Cannabis Conference: Shaping a New Agenda;
Devonshire House, Liverpool, February 19, 2002


The Conference, organised by HIT of Liverpool, was attended by
approximately 200 delegates, mostly from the North West of England.

These consisted of doctors, police, magistrates, probation officers,
students union and youth group representatives, teachers, drug advisors
and counsellors and other drug workers. There were very few cannabis
campaigners present.

The Conference, which ran from 1 pm to about 4,30, consisted of two parts:
the main speakers and a panel to answer questions from the audience.

The conference was introduced by Professor John Ashton, Director of
Public Health, NHS Executive North West.


John Witton, National Addiction Centre, London: Cannabis: a review of
the scientific evidence.
John Witton is to release his book "Cannabis The Facts" later this year.
With the help of slides showing the various claims that cannabis is
dangerous to health, John systematically reduced each claim to mere
speculation. He said that we would hear words such as "may cause" and
"uncertain evidence" throughout his talk.

Cannabis, he stated, is entrenched in society and the harms need to be
based upon a systematic review of the hard evidence. In Britain it is
used by 25% of adults, 6% in the last month. Figures reflected in other
countries - Australia 39% have used, 4% use weekly - USA 35% have used
and 5% use regularly..

The major recent reports worth considering are those from W.H.O., the US
Institute of Medicine 1999, and the National drug and Alcohol Research
Centre 2001.

The main problems in assessing harm are the variation in dosage,
combination with tobacco, the lack of any controlled long-term effect
studies, and the intermittent and limited use over time. These all
complicate the picture.

The usual claimed adverse effects, are rarely observed and mostly in
novice users; these are anxiety, dysploria, panic, paranoia,
psychomotive impairment, something like a psychotic reaction with high
doses, and an increased risk of low weight babies for mothers who smoke.
In fact, these effects are rare.

Potency:
cannabis contains 60 cannabinoids and a claimed increase in THC content
may lead to an increase in the risk of adverse effects. As yet there is
no evidence of that. We must ask whether cannabis users titrate the dose
if THC content is higher. In fact, there is no evidence that overall
THC content has increased over 30 years. The University of Mississippi
research has shown an average content of 3% in the 80's, now only 4%.
There are still plenty of questions about any impact of any increase in
potency.

Psychological harm;
There may appear to be some exacerbation of the symptoms of
schizophrenia and it is claimed that cannabis may precipitate it in
vulnerable people, but it is uncertain whether it can cause it. The
background of users needs to be considered - the evidence is
contradictory.

Dependence:
The definition of the word has been changed to include a difficulty in
stopping use and under that criteria there are reports of dependence.
He criticised the methology.

Gateway to hard drugs:
The role of cannabis is unclear. there are pharmacological, genetic,
sociological explanations too. The sequence of drug use is often
identified as tobacco, alcohol, cannabis, hard drugs, but it is still
unclear.

Driving skills:
There is little evidence of impairment and that is minor. Cannabis has
been found in blood and urine samples of accident victims but the real
role of cannabis in causing accidents is unclear. cannabis-intoxicated
drivers appear more cautious than others in recent studies.

Respiratory system effects:
Cannabis is often used with tobacco but the unpleasant constituents are
tars which are deposited in the lungs. This causes changes in bronchial
tissues and an increase in symptoms of chronic bronchitis - but these
all relate to smoke.

Cancer, the immune system and the reproductive system :
The evidence that cannabis cause cancer is very weak and there is no
evidence that it causes any major impairment to the immune system or
reproductive system.

Cognitive functioning, memory, amotivation:
There is no evidence of chronic brain damage or evidence of any long
term impairment to memory o skills. Evidence of subtle impairment to
memory is emerging in Australia. There is no evidence of amotivation -
it is already there in some users.

Major at-risk people:
adolescents with poor school performance, women who smoke during
pregnancy, those with pre-existing conditions such as schizophrenia or
cardio-vascular problems. There is sparse research into the effects of
passive smoking on children.


Professor Martin Plant, Director, Alcohol 7 health Research Centre, UWE:

Cannabis, other drugs and young people.
Professor Plant stated that the debate has often been a moral one and
objections have often arisen out of a bad perception of cannabis users
(from the 60's - long hair and rock music)

Deaths in the UK form tobacco are 120,000 annually, alcohol accounts for
a further 20,000 plus, whereas all the illicit drugs account for just a
few thousand. Very rarely does cannabis feature in drug death
statistics and in those case it is mostly road accidents. Yet drug
offences have increased over the last 10 years and cannabis accounts for
over 70% of them.


Bob Keizer, drug policy Advisor of the Ministry of Health, Welfare and
Sports of the Netherlands:
In the Netherlands, the state does not interfere with individuals unless
problems are caused - there is no interference with moral standards.
They have diverse politics and the state and church are separated.
The main objective of Dutch policy is to prevent harm. Since 1976,
there has been a distinction between cannabis and other drugs.

Drug use is not prohibited in the Netherlands, as indeed it is not under
the UK Misuse of Drugs Act. Youngsters are not given a criminal record
just for the possession of cannabis. Coffeeshops where small-scale
supply is tolerated account for half the supply.

They have an integrated approach and invest in addict care and
prevention, justice and public order, research and monitoring programs.

The principle is expediency and the goal is to decriminalise users and
separate the market from hard drugs.

Coffeeshops are not legal. They are tolerate and there are strict
conditions:
less than 5 grams per transaction per day,
no hard drug,
no advertising,
no nuisance,
no minors (under 18).

According to the EMCCD in 1999, cannabis use in the last month for 15-16
year-olds in the Netherlands was 14%; in Ireland it is 15%, in the UK
16%, in France 22%, in the US 19%.

Of the general population: Netherlands 5%; UK 9%, France 5%, USA 9%.
Hard drug use: Netherlands 2.5%; UK 5.6%; Sweden (hard line policies)
3%; France 3.9%; Italy 7.2%.

Current Issues:
The problems with back door supplies to coffeeshops which cannot be
regulated. Coffeeshops are still illegal and in the last 3-4 years the
numbers have been reduced from 1200 to 800 due to complaints of
nuisances, mostly from hard drug users.. As yet they have no solution
to supply of coffeeshops.

The Netherlands has found opponents to its policies from around the
world - Germany, Sweden and the USA were main opponents. Germany is now
becoming more progressive and there is little criticism any more.
France is also less critical. They have yet to convince Sweden or the
US. There is more collaboration with European countries.

They are still fighting the hard drug trade and the organised drug trade
although it is practically impossible because they are an open country
with no border controls. They also seize large amounts of cannabis
plants. Unlike most countries, the average age of hard drug addicts is
increasing by one year each year.

Conclusions:
No increase in use,
harm reduction pays off,
no increase in number of hard drug addicts.
The key is the interplay between practice, science and politics.



Panel:
The Question and Answers panel was chaired by Rod Thomson, Joint
Commissioning Manager, Sefton DAT, and consisted of:
Alun Buffry, Legalise Cannabis Alliance;
Detective Chief Inspector Colin Matthews, Merseyside Police;
Dr Tony Quinnell, Senior Clinical Medical Officer, Stockport CDT;
Hywel Sims, Chief Executive ADFAM National;
Brenda Fullard, Regional Coordinator Smoking Cessation, NHS Executive
North West;
plus above three speakers and Professor John Ashton.

There appeared to be very little objection from the audience of
delegates.to a change in law.

Brenda Fullard repeatedly stated that she feared a relaxation of the law
on cannabis would cause an increase in use of tobacco.

The panel were otherwise in support of a relaxation of the law although,
apart from the LCA who proposed full legalisation of possession,
cultivation and supply, there were no real ideas of how a change could
manifest.

Dr Quinnell, who was initially reluctant to publicly announce that he
favoured legalisation, did precisely that in the Manchester Evening News
the next day.

Questions from the audience were about increased risk of progression to
hard drugs, effect of school work, possible effect on organised crime -
and the one token ex-heroin addict who blamed his problems on cannabis.
DCI Matthews said that for some years Merseyside Police have been
reluctant to prosecute for small scale cannabis possession.

Overall, I personally felt that the Conference went very well and was
very educational to most people present, myself included, and I gained a
lot by being able to present LCA views alongside those of the
professionals.

Report by Alun Buffry, National Coordinator, Legalise Cannabis Alliance
http://www.lca-uk.org

 

 

 

After you have finished reading this article you can click here to go back.




This page was created by the Cannabis Campaigners' Guide.
Feel free to link to this page!